| アブストラクト | This retrospective cohort study using the medical data vision (MDV) database included adult patients who had confirmed diagnosis of cGVHD between 2003 and 2023, were prescribed a steroid prior to diagnosis of cGVHD, and received mycophenolate mofetil (MMF), ibrutinib, or ruxolitinib as second- or later-line therapy. Duration of treatment (DoT) and steroid dose reduction during second-line therapy were assessed. Of the 1489 patients whose data were retrieved, 854 were included (median [range] age: 54 [18.0-83.0] years; males: 518 [60.7%]; mean [SD] Charlson Comorbidity Index score: 7.5 [3.5]). Data on second or later lines of treatment were available for 226 patients. The most common second-line therapy used after first-line steroid treatment was MMF (110 [48.67%]), followed by ibrutinib (88 [38.94%]) and ruxolitinib (28 [12.39%]). Median DoT (days) was 95 for MMF, 86 for ibrutinib, and 30 for ruxolitinib. Steroid doses were mostly kept below 0.5 mg/kg/day under all the 3 second-line treatments. These real-world data provide valuable insights into the management of cGVHD with the therapies currently used in Japan. |
|---|
| ジャーナル名 | International journal of hematology |
|---|
| Pubmed追加日 | 2026/3/19 |
|---|
| 投稿者 | Kanda, Junya; Wattanakamolkul, Kittima; Muromine, Hideyuki; Shiga, Kaname |
|---|
| 組織名 | Department of Hematology, Kyoto University Graduate School of Medical Sciences,;Kyoto, Japan.;Integrated Market Access, Johnson & Johnson, 3-5-2, Nishi-Kanda, Chiyoda-Ku,;Tokyo, 101-0065, Japan. KWattan1@ITS.JNJ.com.;Communication and Public Affairs, Johnson & Johnson, Tokyo, Japan.;Medical Affairs, Johnson & Johnson, Tokyo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41851584/ |
|---|
